🔎 Trials Near Me

ホーム › ループス › テキサス

テキサスにおけるループスの臨床試験

テキサス内の拠点で、ループスに関する26件の研究が参加者を募集しています。

テキサス内の都市

公式研究テキスト(英語)

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

  • Novel Research LLC, Bellaire
  • Accurate Clinical Research, League City
  • Epic Medical Research, Red Oak
被験者募集中第3相
12歳〜100歳 · 全性別 · 2026/10/01更新 · NCT06133972

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

  • Prolato Clinical Research Center, Houston
被験者募集中第2相
18歳〜100歳 · 全性別 · 2026/10/01更新 · NCT05268289

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  • Amarillo Center for Clinical Research, Amarillo
  • Precision Comprehensive Clinical Research Solutions - Colleyville, Colleyville
  • Precision Comprehensive Clinical Research Solutions, Euless
  • 他4件
被験者募集中第2相
18歳〜74歳 · 全性別 · 2026/10/01更新 · NCT07409181

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

  • Research Site, El Paso
  • Research Site, Houston
被験者募集中第3相
5歳〜17歳 · 全性別 · 2026/09/30更新 · NCT05835310

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

  • Research Site, Austin
  • Research Site, Baytown
  • Research Site, Colleyville
  • 他3件
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/25更新 · NCT07430306

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  • Amarillo Medical Specialists Rheumatology, Amarillo
  • Amarillo Center for Clinical Research, Amarillo
  • Arthritis and Rheumatology Research Institute, Frisco
  • 他5件
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT07438496

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
  • 他2件
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT03816345

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

  • Research Site, Allen
  • Research Site, Mesquite
被験者募集中第1相
18歳〜65歳 · 全性別 · 2026/09/18更新 · NCT07201558

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

  • North Texas Center for Clinical Research, Frisco
  • Accurate Clinical Research, Humble
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/14更新 · NCT07355218

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

  • Baylor College of Medicine, Houston
被験者募集中第1相
18歳〜60歳 · 全性別 · 2026/09/14更新 · NCT06975787

A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

  • The University of Texas Southwestern Medical Center, Dallas
被験者募集中第2相
12歳〜70歳 · 全性別 · 2026/09/14更新 · NCT07570862

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

  • Allen Arthritis, Allen
  • Arthritis and Rheumatology Research Institute PLLC, Allen
  • Arthritis Care of Texas, Corpus Christi
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/11更新 · NCT07332481

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

  • Sl0044 50738, Bellaire
  • Sl0044 50781, El Paso
  • Sl0044 50673, Fort Worth
  • 他7件
被験者募集中第3相
16歳以上 · 全性別 · 2026/09/04更新 · NCT06617325

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

  • Arthritis Care of Texas - Corpus Christi, Corpus Christi
  • Lone Star Arthritis & Rheumatology Associates, P.C., Denton
  • El Paso Medical Research Institute (MedResearch, Inc), El Paso
  • 他1件
被験者募集中観察研究
16歳以上 · 全性別 · 2026/09/03更新 · NCT07175285

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

  • University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳〜65歳 · 全性別 · 2026/08/26更新 · NCT06121297

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

  • Texas Transplant Institute, San Antonio
被験者募集中第2相
12歳〜65歳 · 全性別 · 2026/08/24更新 · NCT07053800

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

  • Rheumatology Care Center, PLLC, Bellaire
  • Texas Arthritis Center, El Paso
  • Novel Research, LLC., Houston
  • 他3件
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/07/30更新 · NCT07201129

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

  • Stryde Research, Plano
  • Tranquil Clinical Research, Webster
被験者募集中第1相
18歳〜70歳 · 全性別 · 2026/06/05更新 · NCT06613360

A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants

  • US04-0, Irving
  • US02-0, San Antonio
被験者募集中第1/2相健康なボランティア歓迎
18歳〜70歳 · 全性別 · 2026/06/02更新 · NCT06625671

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

  • M D Anderson Cancer Center, Houston
被験者募集中観察研究
18歳以上 · 全性別 · 2026/05/20更新 · NCT04751396

Lupus Landmark Study: A Prospective Registry and Biorepository

  • UT Southwestern Medical Center, Dallas
被験者募集中観察研究
18歳〜110歳 · 全性別 · 2026/04/15更新 · NCT05934149

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

  • MD Anderson Cancer Center, Houston
  • The University of Texas Health Science Center at Houston, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/15更新 · NCT06434363

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

  • Climb Bio Investigative Site #100104, Allen
  • Climb Bio Investigative Site #100101, San Antonio
被験者募集中第1相
18歳〜65歳 · 全性別 · 2026/03/27更新 · NCT07011043

ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。